Sangamo Therapeutics’ investigational gene therapy appears to improve kidney function at 52 weeks for patients with a rare genetic disorder.  | Sangamo Therapeutics’ investigational gene therapy ...

The surgical sealant developer Tissium obtained a groundbreaking FDA clearance for its method of reconnecting severed nerves, ...

ForSight Robotics may be seeing stars after raising $125 million in venture capital funding to power the first human clinical ...

Rivus Pharmaceuticals’ fat-busting, muscle-sparing drug candidate reduced liver fat in a phase 2 trial while showcasing the ...

Mean body weight reductions after 24 weeks ranged from 8.2% to 10.3% in the MDR-001 cohorts, versus 2.5% in the placebo arm.

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

Stuart Therapeutics’ dry eye disease drug has failed to demonstrate that it can increase tear production in a phase 3 test.

Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. | Nektar Therapeutics is enjoying the sweet taste of clinical trial success after ...

A total of $1.25 billion of the money pledged by Royalty has been agreed in exchange for tiered royalties on net sales of daraxonrasib over 15 years. The royalty rate begins at 4.55% on the first $2 ...

Brain metastases are common in ROS1-positive NSCLC, particularly after disease progression. Among 56% with measurable brain ...